
Lecture time
November 6 (Friday) 14:00-15:30Lecture location
Conference Room 302, Building 1, Jinfeng Laboratory
Topic one: Development and transformation of gene replacement therapy drug ZVS101e injection
Introduction to the speaker

Yang Liping , a researcher and doctoral supervisor in the Department of Ophthalmology at Peking University Third Hospital, was selected for the 2025 "Capital High-end Leading Talents Gathering and Training Project" and won the 2025 Outstanding Achievement Award of the Asia-Pacific Macular Retina Society. He has been engaged in the diagnosis, prevention and treatment of hereditary retinopathy for a long time. He has hosted 14 funding projects and published more than 40 SCI papers as the first/corresponding author. The developed BCD gene therapy drug ZVS101e has been submitted to BLA and has been designated as breakthrough therapy in China, RMAT in the United States and PRIME in the European Union. As the first completer, he won the second prize of the Beijing Natural Science Award and the Hospital Science and Technology Innovation Award of the Chinese Hospital Association. Approved 10 national invention patents and PCT patents, and completed conversion of 10 million.
Lecture Introduction
Crystalline retinal degeneration (BCD) is a type of genetic retinal disease with a high incidence in East Asia. Patients mostly develop symptoms in their 20s and become blind in their 40s. Currently, there is no effective prevention and treatment plan. Yang Liping's team has been deeply involved in mechanism research since 2011. After drug screening and structural optimization, it independently developed the original gene therapy drug ZVS101e injection. This product is the world's first BCD gene therapy drug to enter the clinical stage. It has successively obtained China's CDE breakthrough therapy variety, the US FDA RMAT designation (the first domestic gene therapy product to receive this designation), and the European Union's EMA PRIME designation. ; It has completed domestic phase III clinical trials and submitted a marketing application. It is expected to become the world's first BCD treatment drug approved for marketing.
Topic 2: Research on peripheral immunity and treatment of glaucoma
Introduction to the speaker

Huang Lulin, Professor/researcher and doctoral supervisor at Sichuan Provincial People's Hospital affiliated to University of Electronic Science and Technology of China. He has long been committed to research on the genetics and molecular mechanisms of eye diseases, focusing on blinding eye diseases such as glaucoma, age-related macular degeneration, and retinitis pigmentosa. Published 72 academic papers, with academic achievements published as corresponding/first author in journals such as Nature Genetics, Signal Transduction and Targeted Therapy, Nature Communications, etc., hosted 5 projects of the National Natural Science Foundation of China, won the second prize of the National Science and Technology Progress Award, and was selected as the innovative leading talent of Sichuan Province's "Ten Thousand Thousand People Plan" and the academic and technical leader of the Sichuan Provincial Health Commission.
Lecture Introduction
The treatment of glaucoma has long been centered on lowering intraocular pressure. However, some patients continue to suffer optic nerve damage after the intraocular pressure reaches the target, which restricts the long-term prognosis. This study breaks away from the traditional understanding that "primary open-angle glaucoma (POAG) is only a local eye disease caused by trabecular meshwork aqueous outflow obstruction" and proposes that it has dual disorders of the circulatory immune system. Relying on peripheral blood mononuclear cell single cell sequencing, genetic analysis and mouse model verification, the study revealed that immune cell subpopulation imbalance and TNF/IFNG signaling disorder are important mechanisms of ganglion cell loss, and confirmed that POAG risk sites play a pathogenic role by regulating immune-related genes. This achievement breaks the limitation of targets and opens up a new direction for precise regulation of immune pathways for glaucoma gene therapy.
Everyone is welcome to actively participate!